PharmX Technologies (ASX:PHX) Cyclically Adjusted Revenue per Share: A$0.03 (As of Dec. 2025)


ASX:PHX PharmX Technologies Ltd ASX:PHX
38 GF Score
Price A$0.12
GF Value A$0.07
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is PharmX Technologies Cyclically Adjusted Revenue per Share?

PharmX Technologies ASX:PHX 38 Cyclically Adjusted Revenue per Share is A$0.03 as of Dec. 2025. GuruFocus rates ASX:PHX with a GF Score™ of 38/100 and a GF Value™ of A$0.07 (Significantly Overvalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

PharmX Technologies's adjusted revenue per share data for the fiscal year that ended in Jun. 2025 was A$0.012. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is A$0.03 for the trailing ten years ended in Jun. 2025.

During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -9.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of PharmX Technologies was -7.20% per year. The lowest was -23.10% per year. And the median was -12.60% per year.

As of today (2026-07-13), PharmX Technologies's current stock price is A$ 0.12. PharmX Technologies's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Jun. 2025 was A$0.03. PharmX Technologies's Cyclically Adjusted PS Ratio of today is 4.00.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of PharmX Technologies was 5.17. The lowest was 0.19. And the median was 1.10.


PharmX Technologies  (ASX:PHX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

PharmX Technologies's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.12/0.03
=4.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of PharmX Technologies was 5.17. The lowest was 0.19. And the median was 1.10.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


PharmX Technologies Cyclically Adjusted Revenue per Share Related Terms


PharmX Technologies Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for PharmX Technologies's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmX Technologies Cyclically Adjusted Revenue per Share Chart

PharmX Technologies Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.04 0.03 0.03 0.03

PharmX Technologies Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.03 0.00 0.03 0.00

ASX:PHX vs VEEV, BTSG, TEM: Cyclically Adjusted Revenue per Share Comparison

For the Health Information Services subindustry, PharmX Technologies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmX Technologies Cyclically Adjusted PS Ratio vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, PharmX Technologies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where PharmX Technologies's Cyclically Adjusted PS Ratio falls into.


ASX:PHX
38GF Score
PharmX Technologies Ltd ASX:PHX
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmX Technologies Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, PharmX Technologies's adjusted Revenue per Share data for the fiscal year that ended in Jun. 2025 was:

Adj_RevenuePerShare=Revenue per Share /CPI of Jun. 2025 (Change)*Current CPI (Jun. 2025)
=0.012/131.5506*131.5506
=0.012

Current CPI (Jun. 2025) = 131.5506.

PharmX Technologies Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 0.000
201706 0.050 0.000
201806 0.000 0.000
201906 0.038 0.000
202006 0.025 0.000
202106 0.000 0.000
202206 0.020 0.000
202306 0.010 0.000
202406 0.011 0.000
202506 0.012 131.551 0.012

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of A$0.03 mean?
PharmX Technologies (ASX:PHX) has a Cyclically Adjusted Revenue per Share of A$0.03 as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on PharmX Technologies and its competitors.
Is PharmX Technologies' Cyclically Adjusted Revenue per Share too high?
PharmX Technologies' current Cyclically Adjusted Revenue per Share is A$0.03. Overall, PharmX Technologies has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PharmX Technologies' Cyclically Adjusted Revenue per Share compare to VEEV and BTSG?
PharmX Technologies' Cyclically Adjusted Revenue per Share of A$0.03 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Healthcare Providers & Services company?
A good Cyclically Adjusted Revenue per Share depends on the Healthcare Providers & Services industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on PharmX Technologies and its competitors. PharmX Technologies's current Cyclically Adjusted Revenue per Share is A$0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmX Technologies stock overvalued right now?
Based on GuruFocus' analysis, PharmX Technologies (ASX:PHX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.07, compared to a current price of A$0.12 — trading 71.4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is A$0.03. PharmX Technologies' overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For PharmX Technologies (ASX:PHX), the current Cyclically Adjusted Revenue per Share is A$0.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PharmX Technologies (ASX:PHX) Overvalued in 2026?

Based on GuruFocus' analysis, PharmX Technologies stock appears to be overvalued. The current stock price of A$0.12 is trading 71.4% above its estimated GF Value™ of A$0.07. GuruFocus considers PharmX Technologies to be Significantly Overvalued.

Key valuation signals for ASX:PHX:

  • Cyclically Adjusted Revenue per Share: A$0.03
  • GF Value™: A$0.07 vs. price of A$0.12 (71.4% above fair value)
  • GF Score™: 38/100 with 3 warning signs

No single metric tells the full story. See the ASX:PHX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PharmX Technologies Business Description

Address 17 Castlereagh Street, Suite 11.02, Level 11, Sydney, NSW, AUS, 2000
PharmX Technologies Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business.
38GF Score

Get the complete analysis for ASX:PHX

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.12
Price
A$0.07
GF Value